Drawing on electronic health records from nearly 20 million patients with severe obesity, researchers from University of California San Diego find that GLP-1 prescriptions have grown exponentially—from less than 4,600 prescriptions in 2018 to more than 1.4 million in 2025—according to a new real-world analysis presented at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery (ASMBS2026).
Original Source Link
Most severe obesity still goes untreated as GLP-1 use climbs and surgery slips
- Advertisement -